Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FYN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FYN Recombinant Active Kinase / Specific Domains (SH2/SH3) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View FYN Products |
| Gene Delivery | FYN Promise-ORF / Lentivirus Full-length ORF (Fyn-B and Fyn-T isoforms) for stable cell lines. |
View FYN Products |
| Benchmark Ab | Anti-FYN Recombinant Antibody Sequence-verified positive control for IP, Western Blot, and IHC assays. |
View FYN Products |
| Validator | FYN siRNA Set For target knockdown and signaling pathway verification. |
View FYN Products |
| Related Target A | MAPT (Tau) Primary downstream substrate phosphorylated by FYN in Alzheimer's Disease pathology. |
View MAPT Products |
| Related Target B | APP (Amyloid Beta) Upstream mediator of FYN-regulated synaptic toxicity and dendritic spine loss. |
View APP Products |
| Related Target C | SRC Key Src Family Kinase (SFK) member required for selectivity profiling. |
View SRC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Src Family Kinase (SFK) Cross-Reactivity | Homolog panel proteins (SRC, LCK, YES1) strictly verified by mass spectrometry and sequence analysis for counter-screening. |
| Isoform-Specific Targeting (Fyn-B vs. Fyn-T) | Isoform-specific recombinant sequences and Lentiviruses available, ensuring physiological relevance in neuronal vs. immunological assays. |
| Lack of Validated Positive Controls | Recombinant benchmark antibodies matching clinical-grade sequences for assay calibration. |
| Off-Target Phenotypes in Cell Assays | Sequence-verified siRNA sets included to confirm target-specific phenotypic knockdown. |
Live FYN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of FYN kinase spans two distinct frontiers: neurodegenerative diseases (specifically Alzheimer's Disease) and oncology (including glioblastoma and drug-resistant solid tumors). As a non-receptor tyrosine kinase belonging to the Src family, FYN acts as a critical signal integrator. In Alzheimer's Disease, FYN is the molecular bridge linking Amyloid-Beta oligomers to Tau hyperphosphorylation, making its inhibition a prime strategy for halting cognitive decline.
The race for FYN therapeutics is intensifying, with major players shifting focus from traditional small-molecule multi-kinase inhibitors to highly selective FYN inhibitors and Fynomer-based bi-specific modalities. As first-generation therapies reach the clinic, the next wave of R&D is targeting isoform-specific signaling (brain-specific Fyn-B vs. T-cell-specific Fyn-T) to minimize systemic immunosuppressive and hematological toxicities associated with pan-SFK inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | AstraZeneca, Eisai, AB Science | Alzheimer's Disease, ALS, Glioblastoma | Kinase Selectivity Assays (Need high-purity FYN, SRC, LCK, and YES1 active proteins) |
| Fynomer-Antibody Fusions | Covagen (Janssen), Novartis | Inflammatory Diseases, Oncology | Fynomer Scaffold Binding Assays (Need sequence-verified FYN SH3 domain proteins) |
| RNA Therapeutics / siRNA | Academic Consortia, Biotech Startups | Tauopathies, Neurodegeneration | In Vitro Knockdown Validation (Need high-titer FYN Lentivirus and validated siRNA) |